99 related articles for article (PubMed ID: 6241082)
1. [A study of the antitumor action of glyciphosphoramide].
He S; Ji XJ; Zhu TX; Wang NG; Su XL; Cao FZ; Pan ZK; Li ZR; Bao TT; Han R
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1984 Oct; 6(5):334-7. PubMed ID: 6241082
[No Abstract] [Full Text] [Related]
2. [Strategies for studies on mechanism of action of antineoplastic agents].
Kuśnierczyk H
Postepy Hig Med Dosw; 1995; 49(1):85-96. PubMed ID: 8657622
[TBL] [Abstract][Full Text] [Related]
3. [Cytostatic effects of bifolar and chlofiden. Effect on protein synthesis and cell cycle].
Sharykina NI; Bukhtiarova TA; Kudriavtseva IG; Pavlovskaia GP
Ukr Biokhim Zh (1999); 2004; 76(1):123-9. PubMed ID: 15909427
[TBL] [Abstract][Full Text] [Related]
4. [Antitumor properties of 2-phenazinylthioureidotyrosine].
Sidorik OA; Terent'ev AG; Shevchenko IM
Mikrobiol Zh; 1975; 37(4):500-1. PubMed ID: 1214673
[No Abstract] [Full Text] [Related]
5. Cytotoxic activity relative to 4-hydroxycyclophosphamide and phosphoramide mustard concentrations in the plasma of cyclophosphamide-treated rats.
Powers JF; Sladek NE
Cancer Res; 1983 Mar; 43(3):1101-6. PubMed ID: 6825082
[No Abstract] [Full Text] [Related]
6. [Comparative study of the anti-inflammatory, analgesic and antipyretic actions of antitumor preparations].
Trinus FP; Chernov VA; Riabukha TK; Sharykina NI
Vopr Onkol; 1980; 26(5):49-54. PubMed ID: 6966858
[No Abstract] [Full Text] [Related]
7. [Diazo derivatives of amino acids and peptides as possible antineoplastic chemotherapeutic agents. XII. Experimental antineoplastic activity of hydrazone derivatives of N-diazoacetylglycine hydrazide].
Brambilla G; Baldini L; Cavanna M
Boll Soc Ital Biol Sper; 1966 Nov; 42(22):1675-8. PubMed ID: 5982442
[No Abstract] [Full Text] [Related]
8. Comparison of the mutagenicity and teratogenicity of cyclophosphamide and its active metabolites, 4-hydroxycyclophosphamide, phosphoramide mustard, and acrolein.
Hales BF
Cancer Res; 1982 Aug; 42(8):3016-21. PubMed ID: 7046914
[No Abstract] [Full Text] [Related]
9. [Clinical phase II trial of a new antineoplastic drug, glyciphosphoramide (GPM)].
Sun Y
Zhonghua Zhong Liu Za Zhi; 1984 Sep; 6(5):375-8. PubMed ID: 6534723
[No Abstract] [Full Text] [Related]
10. [Clinical phase II trial of a new antineoplastic drug--glyciphosphoramide].
Sun Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1984 Aug; 6(4):273-6. PubMed ID: 6241067
[No Abstract] [Full Text] [Related]
11. [Diazo derivatives of amino acids and peptides as possible antineoplastic chemotherapeutic agents. XI. Experimental antineoplastic activity of N-diazoacetyl-D,L-phenylalanine ethyl ester and of N-diazoacetyl-D,L-phenylalanine hydrazide].
Baldini L; Brambilla G; Cavanna M
Boll Soc Ital Biol Sper; 1966 Nov; 42(22):1672-5. PubMed ID: 5982441
[No Abstract] [Full Text] [Related]
12. [Diazo derivatives of amino acids and peptides as possible antineoplastic chemotherapeutic agents. X. Experimental antineoplastic activity of N-diazoacetyl-D,L-alanine ethyl ester and of N-diazoacetyl-D,L-alanine hydrazide].
Baldini L; Brambilla G
Boll Soc Ital Biol Sper; 1966 Nov; 42(22):1669-72. PubMed ID: 5982440
[No Abstract] [Full Text] [Related]
13. [Clinical phase I trial of a new anti-neoplastic drug--glyciphosphoramide].
Sun Y
Zhonghua Zhong Liu Za Zhi; 1984 Jul; 6(4):293-5. PubMed ID: 6525950
[No Abstract] [Full Text] [Related]
14. Effect of desacetyl vinblastine amide (DVA) against human sarcomas heterotransplanted in nude mice.
Sordillo PP; Hajdu SI; Magill GB; Lesser M; Helson L
Cancer Clin Trials; 1980; 3(4):391-4. PubMed ID: 7428143
[TBL] [Abstract][Full Text] [Related]
15. [Clinical evaluation of glyciphosphoramide used alone and in combination with other drugs].
Wang ZY
Zhonghua Zhong Liu Za Zhi; 1984 Sep; 6(5):379-81. PubMed ID: 6398774
[No Abstract] [Full Text] [Related]
16. [Determination of glyciphosphoramide and its metabolite in plasma and the pharmacokinetics in rats after oral administration].
Wang WJ; Bai JY; Zhu XY
Yao Xue Xue Bao; 1993; 28(10):738-43. PubMed ID: 8009985
[TBL] [Abstract][Full Text] [Related]
17. Increased antitumour activity of mesyl-I-aldophosphamide-perhydrothiazine, in vivo but not in vitro, compared to I-aldophosphamide-perhydrothiazine.
Voelcker G; Pfeiffer B; Schnee A; Hohorst H
J Cancer Res Clin Oncol; 2000 Feb; 126(2):74-8. PubMed ID: 10664245
[TBL] [Abstract][Full Text] [Related]
18. Antitumor properties of selected 1,2,4-triazine derivatives.
Mordarski M; Wieczorek J; Fiszer L; Nantka-Namirski P; Rykowski A
Arch Immunol Ther Exp (Warsz); 1980; 28(5):717-25. PubMed ID: 7212979
[TBL] [Abstract][Full Text] [Related]
19. A review of the preclinical antitumor activity and toxicology of L-asparaginase derived from E. coli.
Charles LM; Bono VH
Cancer Treat Rep; 1981; 65 Suppl 4():39-46. PubMed ID: 7049380
[No Abstract] [Full Text] [Related]
20. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines.
Jain M; Fan J; Baturay NZ; Kwon CH
J Med Chem; 2004 Jul; 47(15):3843-52. PubMed ID: 15239662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
